Replimune Group, Inc. 8-K

What Happened
Replimune Group, Inc. (REPL) filed a Form 8-K on January 12, 2026 under Regulation FD to release an updated corporate presentation that reflects recent business and strategic developments and clinical data for its RP1 and RP2 programs. The company said it will present the updated slides at meetings with analysts and investors, including at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation slides are furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: January 12, 2026 (Form 8-K, Regulation FD disclosure).
• Event: Presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
• Content: Updated slides include recent business/strategic developments and clinical data related to RP1 and RP2 programs.
• Access: Slides filed as Exhibit 99.1; a replay of the JPM presentation webcast will be available at www.replimune.com (“Investors and Media”) for 30 days after the event. Company disclaims any obligation to update the materials.

Why It Matters
Investors get an official, current view of Replimune’s clinical progress (RP1, RP2) and strategy via the company-issued slides and the JPM presentation—useful for evaluating the pipeline and near-term catalysts. Because this is a Regulation FD disclosure, the information is intended to be broadly available to the market; the slides and webcast replay give retail investors direct access to the same presentation being shown to analysts. The filing does not report financial results or management changes.